AQP-1 Polymorphism on Fluid Status in Hemodialysis Patients
- Conditions
- End Stage Renal Disease on Dialysis
- Registration Number
- NCT05275387
- Lead Sponsor
- RenJi Hospital
- Brief Summary
It is a cross sectional observational study. It is to investigate whether AQP-1 polymorphism has any impact on fluid status in hemodialysis patients. The long term stable HD patients in the current center will be enrolled to the study after informed consent. Blood samples will be collected for gene-typing. Fluid status including blood pressure, weekly UF and intra-dialysis body weight change will be collected through their clinical records.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 250
- age 18-70
- ESRD
- maintained HD
- no target weight change during the last week of entering the study and achieve target weight at the end of HD section
- informed consented
- expected survival time less than 3 months
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The total ultrafiltration volume in mls from hemodialysis for the whole week of the recruitment up to 12 weeks The ultrafiltration volume of each HD section of the enrollment week will be recorded. The total ultrafiltration volume of the week is the primary outcome measure. (In most cases, HD patients have three HD sections per week.)
- Secondary Outcome Measures
Name Time Method The total weight gain in kgs of each HD section of the enrollment up to 12 weeks The body weight gain of each HD section of the enrollment week will be recorded. The total body weight gain of the week is the secondary outcome measure. (In most cases, HD patients have three HD sections per week.)
Trial Locations
- Locations (1)
Renji Hospital
🇨🇳Shanghai, Shanghai, China